Imprime PGG in Combination with Monoclonal Antibody Therapy Achieves 64 ... PipelineReview.com (press release) EAGAN, MN, USA I December 10, 2012 I All subjects in a phase 1 study of high risk, chronic lymphocytic leukemia responded to the combination therapy of Imprime PGG®, alemtuzumab (Campath®) and rituximab (Rituxan®) with 64% achieving a complete ... |
